Murepavadin is a ring-shaped synthetic peptidomimetic antibiotic designed to kill only Pseudomonas aeruginosa. A 2018 review called it the first of its class. Its Phase 3 trials were closed in 2019 over kidney safety. This guide covers its structure, target, trials and status. Sources were checked on November 17, 2026.
Quick answer: Murepavadin, also called POL7080, is a macrocyclic peptidomimetic from a family based on the antimicrobial peptide protegrin I. It targets the outer membrane protein LptD of P. aeruginosa. Phase 3 trials in hospital pneumonia were closed in 2019. It is not FDA-approved.
Vitrapep does not sell murepavadin; this page is a reference summary of published research and regulatory information.
What is murepavadin?
Murepavadin is one of a family of “macrocyclic peptidomimetics” (Andolina et al., 2018). A macrocycle is a large ring. A peptidomimetic is a molecule built from peptide-like units to copy a natural peptide’s shape. Our guide to types of peptides covers cyclic peptides and mimetics.
The family began with antibiotics “based on the antimicrobial peptide protegrin I,” a host defense peptide (Srinivas et al., 2010). A 2018 review calls murepavadin a “pathogen specific antimicrobial peptidomimetic.” It also calls it “the first in class of outer membrane protein targeting antibiotics” (Martin-Loeches et al., 2018).
PubChem lists the formula as C73H112N22O16 and the molecular weight as 1,553.8 g/mol (PubChem CID 91824766). Its research code was POL7080.
Murepavadin: key facts
| Fact | Detail |
|---|---|
| Structure type | Macrocyclic (ring-shaped) peptidomimetic |
| Class | Outer membrane protein targeting antibiotic (LptD binder) |
| Molecular formula | C73H112N22O16 |
| Molecular weight | 1,553.8 g/mol |
| Development stage | Phase 3 pneumonia trials closed (2019); Phase 1 of a second formulation, iMPV, completed (reported 2023) |
| Sponsor or developer | Polyphor (Switzerland); later work by Spexis AG |
How does murepavadin work?
Most membrane-active peptides punch holes in bacteria. This family does not. The 2010 study described a “non-membrane-lytic mechanism of action.” It identified the outer membrane protein LptD as a target in Pseudomonas (Srinivas et al., 2010). The lead compound was active against Pseudomonas but “largely inactive against other Gram-negative and Gram-positive bacteria.”
LptD, with its partner LptE, moves lipopolysaccharide (LPS) to the outer surface of the cell. A 2018 lab study found that murepavadin “cross-links to the periplasmic segment of LptD.” The authors expected this binding to block LPS transport (Andolina et al., 2018). They note that the LPS transport pathway is essential in many Gram-negative bacteria.
What is murepavadin being studied for?
Murepavadin is not approved by the FDA for any use. ClinicalTrials.gov lists six Polyphor studies. None is recruiting.
- ventilator-associated P. aeruginosa pneumonia, Phase 2, 25 enrolled (NCT02096328, completed 2016);
- flare-ups of non-cystic fibrosis bronchiectasis, Phase 2 (NCT02096315, terminated 2015);
- ventilator-associated pneumonia, Phase 3, 41 enrolled (NCT03409679, terminated 2019); and
- hospital-acquired pneumonia, Phase 3, 2 enrolled (NCT03582007, terminated 2019).
Both Phase 3 records give the reason for stopping as “Safety data review.” Two Phase 1 studies covered kidney impairment and a drug interaction with amikacin. A later program studied a second formulation, called iMPV. Its UK Phase 1 in healthy volunteers was sponsored by Spexis AG (NHS Health Research Authority, 2020).
What did the key trials show?
Discovery work. The 2010 study tested an early family member, not murepavadin itself. It showed potent activity in a mouse septicemia model, plus biochemical and genetic target work (Srinivas et al., 2010).
Phase 1 in healthy adults. This human study enrolled healthy adults. The authors reported that “murepavadin was well tolerated” and that no limiting toxicity was found (Wach et al., 2018).
Phase 3 PRISM trials. No results are posted on ClinicalTrials.gov for any murepavadin study. We found no peer-reviewed report of the Phase 2 or Phase 3 pneumonia trials. Polyphor stated it closed both Phase 3 studies in July 2019 (Polyphor, 2019).
What side effects have studies reported?
In healthy volunteers, adverse events were described as “transient and generally mild” (Wach et al., 2018). In patients, the key signal was kidney injury. Polyphor cited “a higher than expected frequency of acute kidney injury” in Phase 3, based on rising serum creatinine. It said the decision did not affect its second formulation program.
For iMPV, Spexis reported completing a first-in-human trial in 39 subjects (Spexis, 2023). We found no peer-reviewed safety report from that trial.
What is murepavadin’s regulatory status, and how is it used in research?
Murepavadin is an investigational antibiotic. In April 2019, Polyphor said FDA had designated it a Qualified Infectious Disease Product (QIDP) in four more indications. It already held QIDP status for ventilator-associated bacterial pneumonia (Polyphor, 2019). We found no FDA warning about it. In January 2023, Spexis said its Phase 1 result “clears the way” for trials in cystic fibrosis or bronchiectasis. We found no such trial registered on ClinicalTrials.gov.
In the lab, murepavadin is a tool for studying LPS transport and resistance in Pseudomonas. One study found strains resistant to it carried mutations in the sensor gene pmrB. The authors said this supports “a resistance mechanism shared with colistin” (Romano et al., 2019). Our polymyxin B and colistin guide covers that older drug class.
Frequently asked questions about murepavadin
Is murepavadin a peptide?
It is a macrocyclic peptidomimetic: a ring of peptide-like units designed to copy a natural antimicrobial peptide’s shape.
Is murepavadin FDA-approved?
No. Its Phase 3 trials were closed in 2019, and no approval exists.
Why were the Phase 3 trials stopped?
Polyphor cited a higher than expected frequency of acute kidney injury in patients.
Why does murepavadin act only on Pseudomonas?
Its target, LptD, has a region characteristic of Pseudomonas species. The 2018 binding study links this to its narrow spectrum.
What is POL7080?
POL7080 is Polyphor’s research code for murepavadin.
What to know now
- Structure: macrocyclic peptidomimetic; C73H112N22O16; 1,553.8 g/mol.
- Target: LptD, the outer membrane LPS transporter of P. aeruginosa.
- Evidence: no published efficacy results from Phase 2 or Phase 3.
- Safety: Phase 3 closed in July 2019 over acute kidney injury.
- Status: not FDA-approved; QIDP designations per Polyphor; no active registered trial.
What we’re watching
Any new trial of iMPV in cystic fibrosis or bronchiectasis. Published results from the terminated PRISM trials. Related guides: brilacidin and LL-37.